What is Advaxis Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Advaxis's Probability of Financial Distress (%) is 0.00%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Advaxis's Probability of Financial Distress (%)
For the Biotechnology subindustry, Advaxis's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advaxis's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advaxis's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Advaxis's Probability of Financial Distress (%) falls into.
Advaxis Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 0.00 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.00% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Advaxis (Advaxis) Business Description
Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
| Roy Golan |
officer: Chief Financial Officer |
24 GOLDA MEIR ST., HOLON L3 5840425 |
| Yuval Cabilly |
director |
C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348 |
| Pini Orbach |
director |
C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802 |
| Bridget A Martell |
director |
C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
| Israel Biotech Fund Ii, L.p. |
10 percent owner |
4 OPPENHEIMER ST., REHOVOT L3 7670104 |
| Israel Biotech Fund Gp Partners Ii, L.p. |
10 percent owner |
4 OPPENHEIMER ST., REHOVOT L3 7670104 |
| Murray A Goldberg |
director |
2030 MAIN STREET, SUITE 1500, IRVINE CA 92614 |
| Robert J. Spiegel |
director |
C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
| Vered Bisker-leib |
director |
C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
| Israel Biotech Fund I, L.p. |
10 percent owner |
4 OPPENHEIMER ST., REHOVOT L3 7670104 |
| Amoon Growth Fund Limited Partnership |
10 percent owner |
34 YERUSHALAYIM RD., RAANANA L3 4350110 |
| Israel Biotech Fund Gp Partners, L.p. |
10 percent owner |
4 OPPENHEIMER ST., REHOVOT L3 7670104 |
| Yair Chaim Schindel |
10 percent owner |
YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110 |
| I.b.f. Management Ltd. |
10 percent owner |
4 OPPENHEIMER ST., REHOVOT L3 7670104 |
| Igor Gitelman |
officer: Chief Accounting Officer |
201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070 |
Advaxis (Advaxis) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADXS has been successfully added to your